What is Bioanalytix?
Bioanalytix operates as a premier contract research organization (CRO) dedicated to the biopharmaceutical industry. The company provides a comprehensive suite of analytical services that span the entire product development life cycle, from initial research phases to full-scale commercialization. Their core competencies include advanced protein and gene analytics, bioinformatics, and rigorous quality control protocols.
In an era where regulatory scrutiny is intensifying, Bioanalytix serves as a critical partner for global developers. By offering customized, high-capacity analytical solutions, the firm enables clients to accelerate decision-making processes while ensuring the safety and efficacy of therapeutic products. Their integration of cutting-edge technology with GMP-compliant standards positions them as a vital link in the biopharmaceutical supply chain, facilitating the transition of innovative therapies from the laboratory to the patient.
How much funding has Bioanalytix raised?
Bioanalytix has raised a total of $5M across 3 funding rounds:
Angel/Seed
$858K
Private Equity
$3.8M
Debt
$350K
Angel/Seed (2012): $858K, investors not publicly disclosed
Private Equity (2013): $3.8M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Key Investors in Bioanalytix
PPP
Public-Private Partnership
Undisclosed Investors
Undisclosed Investors
What's next for Bioanalytix?
With the recent capital deployment, Bioanalytix is expected to prioritize the scaling of its analytical capabilities to meet the surging demand for gene and cell therapy development. The strategic focus will likely shift toward enhancing bioinformatics infrastructure and expanding global laboratory capacity to support increasingly complex regulatory requirements.
As the company moves into this next phase of enterprise-level growth, stakeholders will be monitoring its ability to maintain quality standards while increasing throughput. The firm's ability to navigate the intersection of biotechnology and data science will be the primary driver of its long-term competitive advantage in the CRO market.
